TMC Life Sciences Berhad (KLSE:TMCLIFE)

Market Cap	827.39M
Revenue (ttm)	322.59M
Net Income (ttm)	12.97M
Shares Out	1.74B
EPS (ttm)	0.01
PE Ratio	64.19
Forward PE	n/a
Dividend	0.02 (4.67%)
Ex-Dividend Date	Dec 5, 2024

Volume	130,200
Average Volume	138,215
Open	0.4400
Previous Close	0.4450
Day's Range	0.4300 - 0.4500
52-Week Range	0.3650 - 0.7550
Beta	0.52
RSI	68.14
Earnings Date	May 23, 2025

About TMC Life Sciences Berhad

TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara (THKD), a medical bedded center located in Selangor. Its THKD provides women and children health, cancer, orthopedics, ENT, head and neck laser, gastro, hepato, urology, fertility health services. In addition, the company’s reproductive treatment comprises in-vitro fertilisation, preimplantation genetic testing, fertility preservation, laparoscopic surgery, surgical sperm retrieval, and donation...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1994
• Country: Malaysia
• Stock Exchange: Bursa Malaysia
• Ticker Symbol: TMCLIFE

Financial Performance

In 2024, TMC Life Sciences Berhad's revenue was 346.42 million, an increase of 11.19% compared to the previous year's 311.56 million. Earnings were 40.65 million, an increase of 3.54%.